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SUMMARY
Variability of concentrations of s-HLA-I depending on allelic specificity substantiated realisation of research in
population of 248 healthy, unrelated individuals. Defined phenotypes from tissue typing of polymorphic HLA
complex enabled concentrations measurements of 1553 serum samples for HLA - A, B, and C loci determined
antigens. Semi-quantitative technique of inhibition microcytotoxic reaction according to Tait et al. (1981) and
Mclean et al. (1983) with usage of policlonal sera anti-HLA was applied.
For most of numbers of the allelic specificity the concentration of antigen material in soluble form (s-HLA-I) in
blood serum were nominally very high and high. For certain numbers of specificity e.g. HLA- A26, A29, B39,
B52, B56, Cw5, Cw6 the percentage of sera, where the s-HLA concentrations were decreased was observed. The
results were presented as mean values of inhibition microcytotoxic reaction — according to NIH classification.
Authors point on usefulness of results for s-HLA comparative analysis of particular HLA allelic specificity, spe-
cific for certain diseases e.g. Cw7 for SNHL patients and B27 for ankylosing spongilitis
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INTRODUCTION
The role of the class I HLA molecule in soluble form
(s-HLA-I) in all life forms is substantial. Polymorphic
sHLA molecules measured in blood examinations
are similar to HLA antigens placed in membranes of
various cells and tissues. s-HLA molecules have the
same, basic structure and ability to bind with anti-
HLA. s-HLA antigens form complexes with surface
markers of molecules with CD4 and CD8 [1,2]
respectively. Such fact indicates function of s-HLA
molecules in regulatory mechanisms. Another func-
tion attributed to the s-HLA antigens is an ability to
bind, through protein receptors, various endoge-
nous and exogenous peptides [3].
Many years of polymorphic human histocompatibi-
lity complex research unquestionably proved link-
age disequilibrium of individuals in populationÕs
certain disorders. Such stated problem proves that
the research over confirmatory correlation on the
level of soluble HLA antigens is needed.
Recently s-HLA function in various diseases
through quantitative concentration fluctuations in
serum blood samples of examined patients was
evaluated. Puppo et al. [4] were observing correla-
tion between s-HLA-I concentration and AIDS
progress. According to their research s-HLA mole-
cules in HIV-seropositive patients might have an
influence on immunodeficiency pathogenesis.
Similarly, Hagihara et al. [5] established significant-
ly increased class I s-HLA and sCD8 blood serum
concentration straight after and during interferon
therapy in HCV-positive patients. According to
authors, interferon may induce s-HLA-I produc-
tion.
Results of our research suggested correlation s-HLA
concentration with serum examinations of ankylos-
ing spongilitis, sensory-neural deafness, head and
brain injury patients [6,7,8].
Determination of soluble HLA-A2 and HLA-B7
presence was begun in 1970 by Van Rood and also
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by Charlton and ßmijewski [9, 10]. Further
research was continued by Tait et al. [11], McLean
et al. [12] and also by Batko-Flasza and Turowski
[13] with application of the s-HLA-I measurement
method depending on the inhibition lymphocyto-
toxic reaction, independently from ELISA method,
with application of monoclonal antibodies for
s—HLA-I molecules.
The s-HLA concentration fluctuations for particular
specificity of HLA class I in comparison of healthy
and sick individuals seems to be interesting. The
number of letters published in this matter is unsat-
isfactory. We decided to start evaluation of s-HLA-I
concentration research in blood serum of healthy
individualÕs population for particular antigens
determined by HLA-A, HLA-B, HLA-C loci. The
research was possible only with usage of cytotoxic
anti-HLA antibodies for class I HLA antigens with
application of the inhibition lymphocytotoxic reac-
tion. MeasurementÕs performance substantiated
comparative analysis of s-HLA-I concentrations in
blood serum of healthy and sick individuals.
MATERIAL AND METHODS
From venous blood examinations blood serum
from 248 healthy individuals with defined HLA-I
phenotypes was separated. In three serum dilu-
tions, as the source of antigen material in soluble
form, s-HLA concentration was measured.
According to the s-HLA polymorphism and after
taking into consideration homozygotic patterns and
HLA blanc we obtained 1553 samples for multiple
s-HLA concentration measurements.
Concentrations of soluble locus A determined anti-
gens were evaluated in 446 samples, locus B in
787 and locus C in 320 samples. s-HLA concentra-
tions were measured in semi-quantitative microab-
sorption test in inhibition lymphocytotoxic reaction
according to McLean et al. [12] in the following,
our own modification [13].
To each 1 ml of anti-HLA adequate specificity
serum and with predetermined titre various
amounts e.g. 0.5, 0.75, and 1 ml of examined indi-
vidual serum as s-HLA source were added. Krebs-
Ringer buffer solution was added to fulfil to 1 ml
volume. After 3 hours of 20-22¡C incubation the
donor lymphocyte suspension with adequate phe-
notype was added and further step was analogous
with microcytotoxity tissue typing test [14]. The
control reacting reference system was composed of
1 ml of anti-HLA serum for tested phenotype and
1 ml of 3% human serum albumin (HSA) with
8 points in cytotoxic reactive force scale by NIH
approved convention [14].
Inhibition cytotoxic reaction proved presence of
the antigen material in soluble form (s-HLA) in
serum was evaluated from 1 to 8 point scale.
When there was no inhibition reaction, point val-
ues were high and the sum (S) for 3 dilutions of
examined serum amounted in total 24 points, simi-
larly to the control system. Three ranges of lym-
phocytotoxity reaction inhibition was assumed e. g.
very high s-HLA concentration level (1—5 points),
high concentration level (6—10 points), and low
concentration level (11—24 points). According to
the sum (S) inhibition lymphocytotoxic reaction of
particular dilutions A relative value according to
the A=1/ Si . . . . x100 formula was calculated.
Results were formulated in mean values with stan-
dard deviation and with percentage for number of
positive serum of examined individuals.
RESULTS
From s-HLA-A concentrationÕs distribution present-
ed in table 1 comes conclusion that in blood serum
of healthy individuals with present phenotype
HLA-A68 [28], A24 [9] and A32 [19] antigens
s—HLA concentration reached highest values. High
concentration for HLA-A23 [9], A29 [19], A30 [19]
and in single case A31 [19] specificity was not
observed. In summary, from 446 examined sam-
ples in 198 (44.4%) very high s-HLA concentration
values was measured, in 173 (38.8%) high s-HLA
concentration values was detected. Considering
percentage of serum samples for two s-HLA con-
centration ranges, worth mentioning is the fact that
only in 57% of serum samples concerned s-HLA-
A26 [10], 67% s-HLA-A29 [19], 74% s-HLA-A2 and
78% s-HLA—A31 [19]. For the rest of the antigens
percentage fluctuated from 83 to 100. In table 1
inhibition lymphocytotoxic reaction results and A
relative value for single serum samples were pre-
sented, in respect to the fact that the number of
specificity including HLA-A19 is manifested with
low frequency in our population.
The results of s-HLA concentration values for 23
allelic specificity B locus determined and for bi-
allelic Bw4/Bw6 system were presented in table 2.
From 292 examined samples very high s-HLA con-
centration values were observed in almost all solu-
ble HLA-B antigens excluding HLA-B39 [6], B52 [5]
and B56 [22]. Mean values of inhibition cytotoxic
reaction sum and responding it A relative value for
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particular tested serum dilutions, reached highest
values for 21 serum samples of antigen s-HLA-B51
[5] and s-HLA-B58 [17] which appeared in only
one phenotype. Similar concentration values were
observed for s-HLA-B35, B41, B49 [21] and Bw6.
In total, very high s-HLA concentration values for
HLA-B antigens were evaluated in 292 (37.1%)
serum samples from 787 examined. In the table 2
second column presented high s-HLA-B concentra-
tion results with standard deviation were close to
each other due to the former inhibition cytotoxic
reaction ranges selection. High concentration value
of particular s-HLA-B antigens was evaluated in
42.6% serum samples. In total, s-HLA concentra-
tion value in 787 serum samples was high — 79.7%.
Low s-HLA-B concentration values were detected
only in 160 (20.3%) serum samples of all examined
individuals.
In Table 3, in analogous way as above, research
results of s-HLA concentration for 7 numbers of
serologically typing locus C specificity were com-
piled. Very high s-HLA-C concentration values
were evaluated in 101 serum samples (31.6%).
Mean s-HLA concentration value was highest in
reference to soluble HLA-Cw4 and Cw7 antigens
with A relative value amounted 41.0–21.8 and
43.7–27.5 respectively. In 43.8% of the samples
the s-HLA-C concentration value was high. Worth
attention is result of s-HLA-Cw2 and s-HLA-Cw3
concentration values, where the percentage for
high and very high concentration values range
amounted 93 and 95. Low s-HLA concentration
value was evaluated in 67% and 52% in HLA-Cw5
and HLA-Cw6 serum antigen phenotype of exam-
ined individuals. In 320 tested samples with C
locus determined specificity only 22.8% evaluated
low s-HLA-C concentration values.
DISCUSSION
In antigen concentration material research in solu-
ble form (s-HLA-I) in blood serum samples of indi-
viduals not loaded with any pathological process,
was unequivocally proven that concentration val-
ues of most tested s-HLA-ABC antigens were high.
Only for particular number of specificity e.g.
s—HLA-A26 [10], A29 [19], B39 [16], B52 [5], B56
[22], Cw5 and Cw6 some percentage of sera with
low concentration values were observed.
Observations mentioned above seem to prove the
results of the conducted independently from our
work, that in sera of all healthy individuals s-HLA
class I are present. Low concentration values may
be the consequence of subclinical pathological
process in persons treated as ÔhealthyÕ.
The microabsorption in inhibition lymphocytotoxic
reaction as s-HLA determination test is a relatively
simple method, which enables s-HLA determina-
tion for soluble HLA class I polymorphic system
specificity present in serum. Usage of inhibition
cytotoxic reaction was started by Van Rood et al.
[9] and also Charlton and ßmijewski [10] in 1970
sHLA-A N % n
x –SD x –SD
Very high
å A
A1
A2
A3
A11
A23(9)
A24(9)
A25(10)
A26(10)
A29(19)
A30(19)
A31(19)
A32(19)
A68(28)
Total
61
131
78
25
13
40
20
28
3
6
9
17
15
446
33
37
33
64
—
95
45
32
—
—
11
94
100
44.4
20
48
26
16
—
38
9
9
—
—
1
16
15
198
3.5
3.3
3.6
3.4
2.1
3.4
3.9
5.0
2.4
2.3
1.3
1.5
1.2
1.3
1.4
0.9
1.5
—
1.1
1.4
34.9
40.9
31.2
37.3
66.9
30.9
34.3
20.0
50.7
64.1
19.3
27.1
18.0
25.7
34.4
8.7
26.6
—
26.3
35.7
Table 1. sHLA level in sera samples of healthy, adult persons.
å - sum of inhibition cytotoxic reaction; A - relative value; N - number of sera samples; n - number of sera samples in the range of cytotoxic reaction;
% - percentage of positive sera 
% n
x –SD x –SD
High
å A
49
37
55
36
85
2.5
50
25
67
83
67
6
—
38.8
30
48
43
9
11
1
10
7
2
5
6
1
—
173
7.1
7.9
7.7
6.8
8.6
7.0
7.9
8.6
9.0
7.8
8.0
6.0
1.2
1.4
1.5
1.1
1.0
—
1.5
1.3
—
1.5
1.6
—
14.4
13.1
13.5
15.1
11.9
14.3
13.1
11.9
11.1
13.2
12.9
16.7
2.2
2.4
2.5
2.1
1.8
—
2.5
1.8
—
2.5
2.6
—
% n
x –SD x –SD
Low
å A
18
26
12
—
15
2.5
5
43
33
17
22
—
—
16.8
11
35
9
—
2
1
1
12
1
1
2
—
—
75
12.0
14.0
11.9
11.0
23.0
12.0
16
12.0
18.0
15.5
1.6
2.7
1.3
—
—
—
2.3
—
—
2.1
8.5
7.4
8.5
9.1
4.4
8.3
6.4
8.3
5.6
6.5
0.9
1.4
0.8
—
—
—
0.9
—
—
—
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and after them Tait et al. in 1981 [11] and McLean
et al. in 1983 [12]. Published in 1994 Report of the
Second International Soluble HLA (sHLA) work-
shop proves that inhibition cytotoxic reaction tech-
nique was applied independently from ELISA test
in conditions, when highly specific monoclonal
antibodies were used for this method designations
[15]. In 1993 Pouletty et al. [16] in sHLA-B27 des-
ignation in 151 blood serum samples established
that both methods compatibility reached 99.2%.
Application of one monoclonal serum, anti W6/32
most often, for ELISA test created a question for
how much this testing is going to show s-HLA con-
centration value deficit in examined body fluid
material. Results of both techniques will be com-
pared in future. Rubens et al. [17], Westhoff et al.
[18], and Drouet et al. [19] during testing various
molecular s-HLA class I variants pointed on its vari-
ous biologic role. According to authors mentioned
above serum soluble HLA antigens create immuno-
logical complexes with anti-HLA autoantibodies,
contributing to autotolerance preservation.
Additional role of soluble HLA class I antigen in
immunity regulation was annotated by Saririan et
al. [20] pointing on s-HLA-I concentration values
correlation in serum before vaccination with
response to influenza vaccination. According to
recent paper publication possible immunoregulato-
ry function of s-HLA class I molecules in NK cells
identification was suggested. In such context vari-
ous NK cells clones specifically identify various
s—HLA antigens [21].
In accepted by our team in 1995 hypothesis about
coincidence of s-HLA-B27 in pathological mecha-
nism of ankylosing spongilitis and relation
between s—HLA-B27 blood serum concentration
values and clinical status of ankylosing spongilitis
patients. Decrease of s-HLA-B27 blood serum
concentration values of sick patients may occur
sHLA-B N % n
x –SD x –SD
Very high
å A
B7
B8
B13
B14
B18
B27
B35
B37
B38(16)
B39(16)
B41
B44(12)
B49(21)
B50(21)
B51(5)
B52(5)
B55(22)
B56(22)
B57(17)
B58(17)
B60(40)
B61(40)
B62(15)
Bw4
Bw6
Total
60
41
22
7
40
36
35
3
16
6
12
51
6
4
23
6
7
3
16
1
17
5
23
149
198
787
15
44
45
29
52
14
63
100
50
—
67
37
50
75
91
—
14
—
38
100
6
20
52
30
37
37.1
9
18
10
2
21
5
22
3
8
—
8
19
3
3
21
—
1
—
6
1
1
5
12
44
74
292
4.4
3.9
3.4
3.5
3.6
3.8
2.8
3.3
3.6
2.8
3.3
3.0
3.3
1.2
3.0
4.0
1.0
5.0
5.0
3.3
3.7
2.9
0.7
1.4
1.1
0.7
0.8
0.8
1.2
0.6
1.3
1.4
1.2
2.0
2.1
0.5
—
1.1
—
—
—
1.3
1.3
1.3
23.2
31.5
32.3
29.1
29.1
27.3
46.4
30.6
31.5
49.4
35.4
51.1
48.3
92.1
33.3
27.5
100.0
20.0
20.0
35.6
33.5
46.1
4.5
20.5
10.8
5.9
7.0
5.8
27.3
4.8
12.7
32.4
18.4
42.9
44.8
20.1
—
11.3
—
—
—
13.5
20.7
27.7
Table 2. sHLA-B antigens level in samples of healthy, adult person.
å - sum of inhibition cytotoxic reaction; A - relative value; N - number of sera samples; n - number of sera samples in the range of cytotoxic reaction;
% - percentage of positive sera 
% n
x –SD x –SD
High
å A
60
51
32
57
28
39
31
—
44
67
25
22
17
25
9
67
57
100
50
—
71
80
35
48
45
42.6
36
21
7
4
11
14
11
—
7
4
3
11
1
1
2
4
4
3
8
—
12
4
8
71
88
335
8.1
7.5
7.1
8.0
8.4
8.2
7.9
7.1
9.8
8.0
7.1
6.0
7.0
6.0
7.8
7.8
9.0
7.1
8.0
7.8
6.3
8.2
7.8
1.3
1.4
1.2
1.8
1.6
1.7
1.2
1.7
0.5
1.0
1.4
—
—
—
1.7
1.5
—
0.9
1.1
1.7
0.5
1.5
1.4
12.7
13.7
14.3
13.0
12.4
12.7
12.9
14.6
10.3
12.6
14.5
16.7
14.3
16.7
13.4
13.3
11.1
14.3
12.7
13.4
15.9
12.7
13.2
2.2
2.3
2.4
3.0
2.6
2.8
2.2
2.9
0.6
1.6
2.4
—
—
—
2.8
2.7
—
1.9
1.9
2.8
1.2
2.5
2.4
% n
x –SD x –SD
Low
å A
25
5
23
14
20
47
6
—
6
33
8
41
33
—
—
33
29
—
13
—
23
—
13
22
18
20.3
15
2
5
1
8
17
2
—
1
2
1
21
2
—
—
2
2
—
2
—
4
—
3
34
36
160
12.9
13.0
15.4
19.0
15.3
13.8
12.0
15.0
14.0
12.0
14.4
17.5
11.5
13.5
12.5
11.5
13.0
15.2
13.7
2.1
1.4
2.8
—
3.1
2.8
1.4
—
0.6
—
2.8
9.2
0.7
3.5
0.7
0.6
1.0
3.0
2.4
7.9
7.7
6.6
5.3
6.8
7.5
8.4
6.7
7.1
8.3
7.2
6.6
8.7
7.7
8.0
8.7
7.7
6.8
7.5
1.0
0.8
1.1
—
1.3
1.3
0.9
—
0.8
—
1.2
3.5
0.5
2.0
0.5
0.4
0.6
1.2
1.2
127
Turowski G et al — Soluble HLA class I antigens in serum of healthyÉ
due to consumption or synthesis disturbances
thatÕs why purposefulness of s-HLA-B27substitu-
tion through serum transfusion of phenotype HLA-
B27+ blood donors [6].
Zavazava et al. [22] demonstrated low s-HLA con-
centration values for A1 antigens in homozigotic
set, A26 and B40. Drouet et al. [23] stated that
s—HLA antigens is present in serum of healthy indi-
viduals with wide range of concentrations. Mean
s—HLA-B and s-HLA-C concentration value was
phenotype dependent, e.g. statistically substantially
higher, if in tested phenotype antigens HLA-A29
[19] and HLA-B44 were present. Results of so far
performed research point that physiological conse-
quences of s-HLA molecules has not yet been fully
explained and they are still intriguing phenomenon
in human life. Relatively small number of s-HLA
presence publications substantiated conduction of
certain tests in polish population of healthy individ-
uals. Results are helpful for comparative analysis of
s-HLA concentrations in sera of healthy and sick
individuals, particularly in disorders, where s-HLA
molecules participation in organismÕs metabolism
is evident.
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sHLA-C N % n
x –SD x –SD
Very high
å A
Cw1
Cw2
Cw3
Cw4
Cw5
Cw6
Cw7
Total
16
44
38
63
18
40
101
320
19
32
37
35
11
10
42
31.6
3
14
14
22
2
4
42
101
4.7
4.1
3.9
2.9
4.0
4.3
3.1
0.6
0.7
1.1
1.2
—
0.5
1.4
21.7
25.4
28.6
41.0
25.0
23.8
43.7
2.9
4.9
10.4
21.8
—
2.5
27.5
Table 3. sHLA-C antigens level in sera samples of healthy, adult person.
% n
x –SD x –SD
High
å A
56
61
58
35
22
38
41
43.8
9
27
22
22
4
15
41
140
7.9
7.5
7.5
7.7
8.0
8.4
7.5
1.4
1.3
1.7
1.4
2.3
1.5
1.4
13.0
13.7
14.0
13.4
13.3
12.3
13.7
2.4
2.3
2.9
2.4
3.9
2.5
2.5
% n
x –SD x –SD
Low
å A
25
7
5
30
67
52
17
22.8
4
3
2
19
12
21
18
73
12.3
11.3
11.0
14.2
13.2
13.0
14.7
1.3
0.6
—
2.7
1.9
2.1
4.2
8.2
8.8
9.1
7.3
7.7
7.8
7.2
0.8
0.4
—
1.2
1.0
1.1
1.7
å - sum of inhibition cytotoxic reaction; A - relative value; N - number of sera samples; n - number of sera samples in the range of cytotoxic reaction;
% - percentage of positive sera 
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